PDCD1 and gastric adenocarcinoma: There is no large-scale prospective study, and the treatment of advanced HAS relys on advanced gastric adenocarcinoma, which first-line standard treatment is chemotherapy combined with anti-programmed cell death 1 (PD-1) immunotherapy (Ajani et al., 2022; Smyth et al., 2020).